Abstract: OBJECTIVE To investigate the use of warfarin on the basis of gene polymorphisms of VKORC1-1639 G/A and CYP2C93^*. METHODS The 100 patients from October 2016 to February 2018 for warfarin guidelines related to genetic testing were collected, recorded patients basic information (height, weight, etc.). The genotype distribution of VKORC1-1639 G/A and CYP2C93^* was detected by digital fluorescent molecular hybridization(DFMH1), and the initial dose of warfarin was calculated according to the formula of international warfarin pharmacogenomics federation (IWPC) combined with the patien's age, height and weight. RESULTS The actual frequencies of VKORC1-1639 G/A AA, AG and GG genotypes were 84%, 15% and 1% respectively, frequencies of allele A and G were 91.5% and 8.5%. The actual frequencies of CYP2C9 3^* AA, AC and CC were 91%, 9% and 0% respectively, frequencies of allele A and C were 95.5% and 4.5%. Different VKORC1-1639G/A, CYP2C93^* genotype warfarin dosage was different, warfarin dosage was higher in the two group of VKORC1-1639G/A AA & CYP2C93^* AA and VKORC1-1639G/A AG & CYP2C93^* AA, than VKORC1-1639 G/A AA & CYP2C93^* AC group. Warfarin dosage was higher in the group of VKORC1-1639 G/A AA & CYP2C93^* AA, than VKORC1-1639 G/A AG & CYP2C9*1/*1 group, and the differences were statistically significant(P<0.05). CONCLUSION The majority of warfarin metabolic related genes are VKORC1-1639 G/A AA & CYP2C93^* AA group, indicating high mutation rate of VKORC1-1639 G/A. The mutation rate of CYP2C93^* is low, and its polymorphism affects the dose of warfarin among individuals.